Listed by the USPTO as SAOUD, CHRISTINE J
Tech Center 1600 • Art Units: 1641 1642 1645 1646 1647 1657 1674 1678
This examiner grants 58% of resolved cases
SAOUD, CHRISTINE J is assigned to Tech Center 1600 and Art Unit 1641. Across 770 resolved cases, the allowance rate is 57.9% and the interview lift is 37.5%. Median time to allowance is 1063 days. The substantial record permits a meaningful review of examiner outcomes, while the interview measure supports deliberate planning around applicant interviews.
Listed companies are Sphingotec GmbH, Zoetis LLC, and Regeneron Pharmaceuticals Inc. Listed firms include MILLEN, WHITE, ZELANO & BRANIGAN, P.C., BakerHostetler, and Biospark Intellectual Property Law. Practitioners can use this participant history to identify relevant biotechnology and pharmaceutical prosecution experience.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18005082 | METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER | Final Rejection | Individual inventor |
| 18301187 | NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY | Non-Final OA | HOFFMANN-LA ROCHE INC. |
| 18327577 | METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA | Final Rejection | Janssen Biotech, Inc. |
| 19570699 | CANINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 17918853 | CANINE ANTIBODY VARIANTS | Non-Final OA | Zoetis Services LLC |
| 18566029 | METHODS OF TREATING AGE-RELATED FRAILTY WITH INTERLEUKIN-6 | Non-Final OA | University of Basel |
| 18255609 | POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17920118 | PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE | Non-Final OA | Eli Lilly and Company |
| 18121490 | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders | Non-Final OA | BAYER HEALTHCARE LLC |
| 18645694 | METHODS FOR SELECTING EXCIPIENTS AND FOR PREPARING HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS AND OTHER FORMULATIONS COMPRISING PROTEINS | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18617474 | MULTIPLEXED IMMUNOHISTOCHEMISTRY USING RECOMBINANT ANTIBODIES WITH EPITOPE TAGS | Final Rejection | Ventana Medical Systems, Inc. |
| 18140344 | Suppression of Microglial Activation with Innate Lymphoid Cells | Non-Final OA | Janssen Pharmaceutica NV |
| 17327271 | METHODS FOR DETECTING proADM IN A CRITICALLY ILL SUBJECT WHO HAS BEEN ADMITTED TO AN INTENSIVE CARE UNIT | Non-Final OA | B.R.A.H.M.S GmbH |
| 18707591 | RESISTIN-SPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | KIM CELL&GENE |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | Non-Final OA | Maddon Advisors LLC |
| 18685971 | ANTI-NECTIN-4 ANTIBODY, DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | CSPC MEGALITH BIOPHARMARCEUTICAL CO., LTD. |
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | Final Rejection | SPHINGOTEC GMBH |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | Non-Final OA | SPHINGOTEC GMBH |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | Non-Final OA | SphingoTec GmbH |
| 18283652 | METHOD OF DETERMINING PROGNOSIS OF CHRONIC KIDNEY DISEASE | Non-Final OA | RANDOX TEORANTA |
| 18547382 | PROTEIN-BASED THERAPIES FOR OCULAR CONDITIONS | Non-Final OA | The University of North Texas Health Science Center at Fort Worth |
| 18257749 | ANTI-BCMA ANTIBODY, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Non-Final OA | WUHAN YZY BIOPHARMA CO., LTD. |
| 18256276 | HALF-LIFE EXTENDING COMPOSITIONS AND METHODS | Final Rejection | Janux Therapeutics, Inc. |
| 18319817 | METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE | Final Rejection | Ascendo Biotechnology, Inc. |
| 18029043 | RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS OF MAKING AND USING THEREOF | Non-Final OA | BAILI-BIO (CHENGDU) PHARMACEUTICAL CO., LTD. |
| 17905496 | PHARMACEUTICAL FORMULATION COMPRISING BEVACIZUMAB | Final Rejection | SHANGHAI HENLIUS BIOTECH, INC. |
| 17801135 | Recombinant calprotectin | Non-Final OA | Buehlmann Laboratories AG |
| 17764098 | ANTIBODIES SPECIFIC TO GLYCOSYLATED CTLA-4 AND METHODS OF USE THEREOF | Final Rejection | STCUBE & CO. |
| 17607989 | A Composition And Method For Improving The Profile Of Blood | Non-Final OA | Manukamed Functional Food Ltd |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy57.9% of resolved applications examined by Christine J Saoud were allowed (770 resolved cases), compared with 45.2% across Art Unit 1641 over the last five years.
This examiner's interview lift is +37.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Christine J Saoud took 1,063 days on average from filing to allowance.
Christine J Saoud examines applications in Art Unit 1641 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
